SEOUL -- TransThera Biosciences, a clinical-stage biotech company in China, will develop and commercialize LG Chem's new drug candidate for autoimmune diseases in the Chinese market. The two companies would strengthen their strategic partnership and accelerate the development of new drugs.
LG Chem, a chemical wing of South Korea's LG Group, has developed LC510255, a new orally administered drug that promotes the expression of an S1P1 protein that controls immune hypersensitivity. Through pre-clinical and first-stage clinical trials, LG Chem claimed to have identified reduced immune cells and high selectivity of S1P1 proteins.
LG Chem, which has a business division engaged in pharmaceutical products, said that it has signed a partnership agreement with TransThera Biosciences on LC510255. "We will do our best to provide new treatment opportunities for patients with autoimmune diseases through successful drug development," LG Chem Life Sciences head Son Jee-woong said in a statement on April 28.
The partnership began in August 2020, when LG Chem agreed to introduce TransThera's new drug candidate for the development of new non-alcoholic steatohepatitis (NASH) drugs. NASH can be defined as the liver manifestation of a metabolic disorder and is the most severe form of non-alcoholic fatty liver disease closely related to the triple epidemic of obesity, pre-diabetes, and diabetes.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.